Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Investing.com - FMC (NYSE: FMC) reported fourth quarter EPS of $1.07, $0.01 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $1.15B versus the consensus estimate of $1.24B.
Guidance
FMC sees FY 2024 EPS of $3.23-$4.41 versus the analyst consensus of $3.80.
FMC sees FY 2024 revenue of $4.50B-$4.70B versus the analyst consensus of $4.58B.
FMC's stock price closed at $60.40. It is up 20.53% in the last 3 months and down -52.11% in the last 12 months.
FMC saw 0 positive EPS revisions and 14 negative EPS revisions in the last 90 days. See FMC's stock price’s past reactions to earnings here.
According to InvestingPro, FMC's Financial Health score is "good performance".
Check out FMC's recent earnings performance, and FMC's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar